TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00486239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TLE Arm 1
Description: Behavioral/cognitive testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Memory Test
Description: Behavioral/cognitive Measure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Memory Testing
Description: Behavioral/cognitive testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Memory Testing
Description: Behavioral/cognitive testing
Study: NCT03502772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
Study: NCT02357277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: inhaled glucocorticoid budesonide as dry powder inhaler

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaler
Description: inhaled placebo
Study: NCT03568786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-inspiratory pause 10%
Description: Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-inspiratory pause 30%
Description: Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
Study: NCT01634750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ManNAc
Description: Single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ManNAc
Description: Single dose
Study: NCT04071483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical transforaminal epidural steroid injection
Description: Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical transforaminal epidural steroid injection
Description: Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
Study: NCT00580294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone
Description: IV PO
Study: NCT01655212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
Study: NCT00419432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Observational Analysis (prior to procedure)
Description: Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
Study: NCT01728259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Given PO
Study: NCT00789308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Sulfated Dextran (LMW-SD)
Description: Inhibitor of IBMIR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)
Description: Cell proliferation inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)
Description: Cell proliferation inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf® (Tacrolimus) OR Cyclosporine
Description: Calcineurin inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf® (Tacrolimus) OR Cyclosporine
Description: Calcineurin inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simulect® (Basiliximab) - at 2nd or 3rd transplant
Description: Monoclonal IL-2 receptor blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simulect® (Basiliximab) - at 2nd or 3rd transplant
Description: Monoclonal IL-2 receptor blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klexane® (Enoxaparinsodium)
Description: Anticoagulation Prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klexane® (Enoxaparinsodium)
Description: Anticoagulation Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)
Description: Anticoagulation Prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)
Description: Anticoagulation Prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel® (Etanercept)
Description: Anti-Inflammatory Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel® (Etanercept)
Description: Anti-Inflammatory Therapy
Study: NCT03283358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered follow up
Study: NCT04953520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-CT fusion imaging
Description: The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of ultrasound-CT fusion imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pure ultrasound guidance
Description: The patient undergoes lumbar nerve root block guided puncture needle placement under the guidance of pure ultrasound guidance
Study: NCT00419432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)
Description: This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
Study: NCT00741221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
Study: NCT04287556

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro contracture test (IVCT)
Description: In vitro study of muscle contraction after exposure to different substances (caffeine and halothane).

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro test of hypermetabolism in B lymphocytes
Description: In vitro study of the activation of lymphocytes B after being incubated with a cocktail of primary antibodies and measuring the acidification in response to the RyR1, 4-CmC agonist, using ryanodine as a positive control.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic test
Description: Analysis of genes related to MH (CACNA1S and RYR1).
Study: NCT01728259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01470339

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: duloxetine 60mg once a day for 5 weeks
Study: NCT03148925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SELA-070
Description: Sub-cutaneous injection, multiple dose
Study: NCT04192214

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BC 007
Description: 1350 mg of BC 007
Study: NCT02726776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension in a harness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension in a harness
Study: NCT01470339

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: duloxetine
Description: duloxetine 60mg once a day for 5 weeks
Study: NCT04185467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention (rehabilitation exercise)
Description: Patients in intervention group (exercise rehabilitation) will receive a multimodal program which includes a 90 minute program at the hospital gymnasium in a supervised environment a minimum of once but up to twice per week. Rehabilitation will include aerobic (brisk walking), resistance training and 30 minutes of 8 style Tai Chi. Participants will be advised to walk on days of non-attendance - this will be individualised with the aim to have participants increase to 30 minutes walking per day.
Study: NCT03307447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300 mg subcutaneous injection
Study: NCT00003995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT03607682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields (TTF) Therapy
Description: Undergo TTF therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-200A Device
Description: Undergo TTF therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02435173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDZ173
Description: CDZ173 10 and 70 mg capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDZ173
Description: CDZ173 10 and 70 mg capsules for oral administration.
Study: NCT03148925

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sub-cutaneous injection, multiple dose
Study: NCT02435173

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules for oral administration
Study: NCT04555213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 Suppository
Study: NCT04055298

Intervention type: DEVICE
Group type: OTHER
Intervention: SMASS-Triage
Description: SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
Study: NCT02726776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Climbing
Study: NCT00756444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
Study: NCT04555213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 Suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 Suppository
Study: NCT00756444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
Study: NCT04006457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 50 mg oral tablets/capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 50 mg oral tablets/capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Description: Single intramuscular injection administered to patients participating in the vaccine sub-study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Description: Single intramuscular injection administered to patients participating in the vaccine sub-study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Description: Single intramuscular injection administered to patients participating in the vaccine sub-study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
Description: Single intramuscular injection administered to patients participating in the vaccine sub-study
Study: NCT04555213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 Suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 Suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 Suppository
Study: NCT00001309

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin C
Description: Outpatient subjects will be encouraged to consume vitamin C in foods. As inpatients, vitamin C deficiency will be induced by placing subjects on a tightly restricted scorbutic diet. Plasma vitamin C will be monitored several times per week. When subjects have achieved a plasma ascorbate concentration of 5-10 micromolar, blood sampling and urine collection over 24 hours will be performed. After platelets and leukocytes are collected, ascorbate repletion will begin. Escalating doses of ascorbate will be administered orally and intravenously for the remainder of their inpatient admission. Total daily doses of 30mg, 60mg, 100mg, 200mg, 400mg, 1000mg and 2500mg will be given in two divided doses. Bioavailability of ascorbate will be determined at each dosage increment. When plasma ascorbate concentration reaches steady state for each dose, subjects will undergo 36 hr plasma sampling and a timed 48 hr urine collection.
Study: NCT02688855

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Combined Magnetic Field OL1000 Bone Growth Stimulator
Description: Active CMF OL1000 Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Combined Magnetic Field OL1000 Bone Growth Stimulator
Description: Sham CMF OL1000
Study: NCT00265941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab 400 mg/m\^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m\^2 IV weekly for 7 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Cisplatin 100 mg/m\^2 IV on days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 100 mg/m\^2 IV on days 1 and 22

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Accelerated Fractionation by Concomitant Boost
Description: 3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Fractionation by Concomitant Boost
Description: 3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy
Description: 70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: 70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
Study: NCT03425656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Description: Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab plus docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
Description: Trastuzumab (8 mg/kg IV loading dose at cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for four 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
Study: NCT02859701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: IV AK002

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02424539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFNS
Description: FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFNS
Description: FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
Study: NCT00337636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to implant human CNS stem cells (HuCNS-SC)
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication to suppress the immune system
Description: Immunosuppression for 12 months post transplant
Study: NCT03500107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Emitting Diode (LED) 401 +/- 5nm
Description: The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
Study: NCT01821677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00085969

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.04 mL twice daily
Description: Subcutaneously injected, 0.04 mL, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.04 mL once daily
Description: Subcutaneously injected, 0.04 mL, once daily
Study: NCT03442465

Intervention type: BEHAVIORAL
Intervention: Toronto Extremity Salvage Score
Description: Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.

Intervention type: BEHAVIORAL
Intervention: Toronto Extremity Salvage Score
Description: Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
Study: NCT02606747

Intervention type: OTHER
Description: routine blood sugar control